Hameln Pharmaceuticals Receives FDA Warning Letter - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Hameln Pharmaceuticals Receives FDA Warning Letter


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a Warning Letter to Hameln Pharmaceuticals GmbH after observing “significant” cGMP violations for finished pharmaceuticals at the company’s facility in Hameln, Germany. The letter, dated Dec. 17 2012, was posted on FDA’s website earlier this week.

The Warning Letter relates to an inspection conducted in June 2012. FDA observed several violations including a lack of education, training and experience for specific tasks. As an example, FDA says that one employee examining plates was unable to read and accurately record microbial counts. Employees involved in sterile filling operations were also not following procedures, such as glove-change frequency, the handling of dropped objects, personnel monitoring and sample acquisition.

Since the inspection, Hameln has issued several responses to FDA. Although the company has retrained employees, however, FDA wants to know why the company was unable to identify and mitigate the lapses in the first place.

FDA also noted a lack of (or inappropriately followed) written procedures designed to prevent microbial contamination of sterile drug products, citing that FDA smoke study videos were not sufficient to evaluate Class A airflow. Hameln has provided a written evaluation of the studies, but FDA is not convinced and has asked for additional evidence or a repeat of smoke studies.

Another observation of the FDA was Hameln’s failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas. For example, FDA said, “There was no justification for the failure to place nonviable probes in locations related to the risk of exposed containers and product.” FDA also claims that nonviable probes were in locations that provided information of little value in terms of monitoring how environmental conditions may impact the product.

In one of its responses, Hameln explained that one of its restricted barrier system units is difficult to use and that the company would redesign it by March 31, 2013. FDA has asked the company to explain the risks that may have occurred when producing previous batches with the old design, as well as risk-mitigation efforts.

FDA also added that inspectors observed additional violations, which are not detailed in the letter.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here